Venture Capital

A new device gets the CE Mark to modernize a 60-year-old cardiac test, promising clearer, faster diagnosis of shunts linked to stroke in millions.

A new brain-inspired chip placed inside the tire promises to give autonomous vehicles a real-time sense of road grip, preventing accidents before they happen.

Anduin launches Instant Extraction, using AI to digitize offline investor documents, aiming to end the era of manual data entry for fund managers.

Chinese robotics firm KaiTu Technology debuts its AI-powered forklifts and AMRs in Silicon Valley, signaling a new era of global competition in automation.

Imviva Biotech's new CAR-T therapy shows potential for durable remission in lupus, moving advanced cell treatments beyond cancer to autoimmune disease.

Investment firm Malar Group backs wellness startup Attaboy Labs, betting on clinical science over marketing hype in the booming supplement industry.

A new conversational AI tool promises to act as an expert whisperer for R&D teams, unlocking siloed materials data and accelerating innovation.

Berlin-based Tacalyx is advancing its lead drug, TCX-201, to the clinic, targeting a novel class of antigens once thought impossible to drug.

A new stem cell therapy promises a one-time cure for hemophilia A, and the FDA is clearing the path. Could lifelong, costly infusions become a memory?

The Defense Logistics Agency has awarded a landmark $50M contract to Corsha to rapidly deploy identity-based Zero Trust security across its critical OT systems.

As DLH Holdings prepares its Q2 results, investors watch to see if it can navigate contract losses and prove its mettle in the federal tech space.

With patient enrollment accelerating for its novel lung fibrosis drug, LTI-03, Rein Therapeutics signals progress in a field desperate for new options.

Oral care leader quip and skincare giant Glowbar partner, signaling a major shift toward simplified, habit-driven wellness. What does this mean for you?

Seattle startup CounterX Therapeutics to present its novel overdose prevention drug at a top investor event, signaling new hope in the fentanyl crisis.

Snap CEO Evan Spiegel will headline Augmented World Expo, unveiling new tools from subsidiary Specs Inc. and charting a course for human-empowered spatial AI.

The largest deal in epigenetic testing sees TruDiagnostic's parent buy Dr. David Sinclair's Tally Health, aiming to make personalized longevity mainstream.

The U.S. Highbush Blueberry Council is betting on startups to find new uses for blueberries in everything from skincare to pet food. Here's what's next.

With a new industry giant on its board and fresh funding, Phagenesis is set to scale its groundbreaking neuromodulation therapy for swallowing disorders.

Shanghai's Vivacta Bio raises over $50M from top VCs to revolutionize cancer treatment with its pioneering in vivo CAR-T therapy, GT801.

A novel, FDA-cleared wound therapy is rolling out to military and veteran hospitals, aiming to rewrite the rules of healing for the most complex injuries.